Side-by-side comparison of AI visibility scores, market position, and capabilities
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
Cloud-based EHR and care coordination platform for long-term and post-acute care organizations. Mississauga, Canada. Raised $172M+, unicorn. Serves 27,000+ care facilities across North America.
PointClickCare is North America's leading cloud-based software platform for the long-term and post-acute care (LTPAC) market, headquartered in Mississauga, Ontario, Canada. Founded in 1999, the company has raised over $172 million and achieved unicorn valuation status. PointClickCare serves over 27,000 care facilities including skilled nursing facilities, senior living communities, assisted living centers, and home health agencies across the United States and Canada. The platform provides electronic health records (EHR), billing, care coordination, and business intelligence capabilities.\n\nPointClickCare's platform is built around the complex clinical and regulatory workflows unique to post-acute care, which differ substantially from acute hospital EHR requirements. The system manages MDS assessments, care planning, medication administration records, therapy documentation, and the complex billing requirements for Medicare, Medicaid, and managed care payers. Its network effect is significant — because PointClickCare connects so many facilities, care transitions between hospitals and post-acute settings can be managed with streamlined data exchange.\n\nThe company has expanded through strategic acquisitions including Collective Medical, which added care transition and high-risk patient identification capabilities powered by a large hospital and payer data network. PointClickCare's Marketplace ecosystem allows third-party technology vendors to integrate with the platform, creating an app store model that extends its functionality without requiring PointClickCare to build every adjacent capability. As value-based care models push accountable care organizations to manage patient outcomes across the full episode of care, PointClickCare's position at the post-acute node of the care continuum becomes increasingly strategically important.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.